Ciprofloxacin
- Generic Name
- Ciprofloxacin
- Brand Names
- Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18FN3O3
- CAS Number
- 85721-33-1
- Unique Ingredient Identifier
- 5E8K9I0O4U
- Background
Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.
The first ciprofloxacin containing product was FDA approved on 22 October 1987.
- Indication
Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...
- Associated Conditions
- Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae
- Associated Therapies
- -
Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 351
- Registration Number
- NCT00062231
- Locations
- 🇸🇰
National Cancer Institute - Bratislava, Bratislava, Slovakia
🇹🇷Ibn-i Sina Hospital, Ankara, Turkey
🇩🇪Charite - Campus Charite Mitte, Berlin, Germany
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Gary Morrow
- Target Recruit Count
- 212
- Registration Number
- NCT00002850
- Locations
- 🇺🇸
CCOP - Columbus, Columbus, Ohio, United States
🇺🇸St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States
🇺🇸Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 90
- Registration Number
- NCT00000641
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
🇺🇸NY Univ. HIV/AIDS CRS, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.